At Colossal Biosciences, we endeavor to jumpstart nature’s ancestral heartbeat. To see the Woolly Mammoth thunder upon the tundra once again. To advance the economies of biology and nutrition. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet, can breathe easier.
These things, which were not achievable before, are now. In our laboratories. Through our breakthroughs in CRISPR and genetic engineering.
We are leading the new charge of bioscience. We accept the responsibility. And we can see the light at the end of it all.
Many companies claim they're going to change the world.
At Colossal, we believe that the world doesn't need to be changed.
Which is exactly what we're doing through purposeful advancements in science. Because when it comes to our planet, science is everything.
“In 2014, I asked my friend Elon Musk who he knew who was poised to make profound changes in the field of genomics, and he said: George Church.
So in June 2014, I visited George at his lab in Boston. I immediately knew I’d be looking for an opportunity to collaborate with George. Global Space Ventures is excited to be backing Colossal. George Church’s personal passion for the mission, combined with the stellar team assembled by serial entrepreneur Ben Lamm, is at the perfect intersection of audacious yet achievable. The path to de-extinction is now at hand, and leveraging CRISPR/Cas9 technology, to bring back extinct species and preserve those that we have, will have profound importance to humanity.”
Through technological and engineering breakthroughs in biosciences and genetics, Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition.
Colossal will revolutionize history and be the first company to use CRISPR technology successfully in the de-extinction of previously lost species. On the journey we will build radical new software tools and technologies to advance the science of genomics overall.
"I've followed the ground-breaking work of George Church for years. I have also invested in and coached Ben Lamm when he founded Hypergiant. These two are a powerhouse team who have the ability to completely shift our understanding of modern genetics while developing innovative technologies that not only help bring back lost species, but advance the entire industry. I am proud to be an investor in their journey."
World Famous Life-Coach, Author,
Investor and Entrepreneur
[ colossal investor ]
As grateful citizens of the universe, we recognize the value of habitable environments for our species and those around us. As tenants of Earth, currently the only livable planet in our solar system, it is not enough just to be grateful, but we must also be active in a role as custodians and defenders of the nature which sustains life.
Balance is not for us to determine. It has been refined for billions and billions of years by forces such as gravity, geology and evolution. Thus it is not our role to pick and choose the winners and losers. But merely to respect all living things - past and present.
Today, the Woolly Mammoth. But tomorrow, maybe the cure for blindness, eradication of tumors and elimination of disease. The potential of bioscience is almost unlimited, and we are at the forefront, pushing the boundaries.
At Colossal we are driven by the forces of virtue and moral good - working for a healthier planet, a healthier human populace and a pursuit of that which we recognize as goodness, compassion and honest, pure science.
Colossal expands the boundaries of what is possible with CRISPR and other cutting edge biological engineering technologies, always with a commitment to responsible science and stewardship of our planet’s natural diversity. We are guided by these values:
[ Unbreakable PRINCIPLES ]
"Healing our Earth's ecosystems is of critical planetary importance.
The overwhelming success of the human species has come at a profound price, the massive global loss of biodiversity and destruction of basic ecological services that have been tuned over millions of years to support life. Colossal is pioneering an approach to ecosystem restoration and bioscience innovation that can help reverse this trend, restoring some balance to the world."
Managing Partner JAZZ Ventures, founder & CEO of NeuroInsights, best-selling author, founder of Neurotechnology Industry Organization, creator of Experiential Technology and NeuroGaming Conference and Expo
[ Colossal Investor ]
It will be up to humans to reverse the harm caused by humans. Hence, our team is intentionally selected to accomplish exactly that - comprised of world-leaders in science and genetics to ecology and industry.
Ben Lamm is the co-founder and CEO of Colossal. Ben is a serial technology entrepreneur driven to solve the most complex challenges facing our planet. For over a decade, Ben has built disruptive businesses that future-proof our world. In addition to leading and growing his own companies, he is passionate about emerging technology, science, space and climate change. Active in angel investing, incubators and startup communities, Ben invests in software and emerging tech, and is deeply engaged in the technology, defense and climate change communities.
Prior to Colossal, Ben served as the founder and CEO to a number of companies, including Hypergiant, an enterprise AI software company focused on critical infrastructures, space, and defense; Conversable, the leading conversational intelligence platform that helps brands reach customers through automated experiences acquired by LivePerson; and Chaotic Moon, a global creative technology powerhouse acquired by Accenture. Ben was also the co-founder of Team Chaos, a consumer gaming company acquired by Zynga.
Ben is a fellow of the Explorer’s Club, whose mission is to promote the scientific exploration of land, sea, air, and space by supporting research and education in the physical, natural and biological sciences. He also serves as a Scientific Advisory Board member on the Planetary Society and sits on the Advisory Board for the Arch Mission. Ben has appeared as a thought leader in many publications, including the Wall Street Journal, New York Times, Forbes, Entrepreneur, Wired, TechCrunch, VentureBeat, and Newsweek on topics such as innovation, technology and entrepreneurship.
George Church, Ph.D. acts as the co-founder and lead genetics advisor for Colossal. He is a professor at Harvard and MIT, runs the Church lab at the Harvard Medical School, and is a Core Faculty member of the Wyss Institute at Harvard where he leads the Synthetic Biology Platform. Church is a recognized leader in genomics, having pioneered a number of advances and breakthroughs that have helped advance the entire field.
In 1984 with Wally Gilbert, Church developed the first direct genomic sequencing method and barcode-multiplexing tags. This led to automation and software used for the first cellular genome sequence (Helicobacter) in 1994, which evolved into ‘in-situ sequencing’ (1999) and ‘next-generation sequencing’ (2014).
Church then pioneered chip-based DNA libraries, genome editing, and stem cell engineering. He also pioneered new privacy, biosafety, human engineering, environmental, biosecurity, and bioethics strategies and training. Today, he and his group champion open-access human genome data.
For his achievements and direct contributions to genomics and the sciences as a whole, Church has received numerous awards. Some of his most prestigious recognitions include National Academy of Sciences, National Academy of Engineering, the Heptannual Bower Award, and Prize for Achievement in Science from the Franklin Institute.
At Colossal we're bringing together the greatest minds and leaders in technology, translational medicine, chemical engineering, biotechnology, molecular genetics, and software along with ground breaking entrepreneurs to help guide us on our path. Our team includes practicing physicians, researchers, authors, inventors, professors, and winners of the Anitschkow Prize, National Medal of Technology and Innovation, Breakthrough Prize in Life Sciences and the Harvey Prize.
Professor of Ecology and Evolutionary Biology at UC Santa Cruz and HHMI Investigator
[ COLOSSAL SCIENTIFIC ADVISORY BOARD MEMBER ]
Beth Shapiro is an evolutionary biologist who specializes in the genetics of ice age animals and plants. As Professor of Ecology and Evolutionary Biology at UC Santa Cruz and HHMI Investigator, Beth uses DNA recovered from bones and other remains to study how species evolved through time and how human activities have affected and continue to affect this dynamic process. Her work focuses on organisms ranging from influenza to mammoths, asking
questions about domestication, admixture, speciation, and pathogen evolution. Her current work develops techniques to recover increasingly trace amounts of DNA such as from environmental and forensic samples. A 2009 MacArthur Fellow, Beth is also an award-winning popular science author and communicator who uses her research as a platform to explore the potential of genomic technologies for conservation and medicine.
by Beth Shapiro
When the 2020 Nobel Prize was awarded to the inventors of CRISPR, the revolutionary gene-editing tool, it underlined our amazing and apparently novel powers to alter nature. But as biologist Beth Shapiro argues in Life as We Made It, this phenomenon isn’t new. Humans have been reshaping the world around us for ages, from early dogs to modern bacteria modified to pump out insulin. Indeed, she claims, reshaping nature—resetting the course of evolution, ours and others’—is the essence of what our species does.Learn More +
by Beth Shapiro
Could extinct species, like mammoths and passenger pigeons, be brought back to life? In How to Clone a Mammoth, Beth Shapiro, an evolutionary biologist and pioneer in ancient DNA research, addresses this intriguing question by walking readers through the astonishing and controversial process of de-extinction. From deciding which species should be restored to anticipating how revived populations might be overseen in the wild, Shapiro vividly explores the extraordinary cutting-edge science that is being used to resurrect the past. Looking at the very real and compelling science behind an idea once seen as science fiction, How to Clone a Mammoth demonstrates how de-extinction will redefine conservation's future.Learn More +
We’re also partnering with leaders in critical industry sectors who have deep experience and decades of relationships with Fortune 500 leaders and beyond. This board ensures that we ethically meet our business objectives so our research and development into biosciences can continue to benefit humankind indefinitely.
The ultimate aim of de-extinction and rewilding is to restore delicate, ecosystems back to healthier, more planet-friendly states. Thus it’s critical that we partner with some of the sharpest and most experienced minds in conservation today. For their leadership and advisement, we are forever grateful.
“I’m very excited to invest in Ben and George's new company, Colossal,”
said lead investor Thomas Tull.
“The platform they are building will have a meaningful impact on both ecology and cutting-edge biotechnology.”
We’re proudly partnered with some of the greatest teams and organizations from around the globe. Each equally committed to our vision and shared objectives of restoring the world to a healthier state, de-extinction, preventing, or staving off extinction, and protecting all wildlife in general.
Thomas Tull is founder and CEO of Tulco, a privately held holding company that partners with entrepreneurial companies posed to transform old-line industries using cutting-edge technology. Tull is the founder and former CEO of the well-known film production company Legendary Entertainment
U.S. Innovative Technology (“USIT”) is an investment firm that backs early- and growth-stage technology companies with dual-use applications to the commercial sector and defense industry, including, defense-tech, artificial intelligence, logistics, space, tech bio and future of compute. USIT was founded by American technologist and visionary investor Thomas Tull.
Breyer Capital is a premier global venture capital and private equity fund focused on catalyzing high-impact entrepreneurs in the United States and China.
IQT connects cutting-edge technology, strategic investments, and purpose to enhance and advance national security capabilities for the U.S. and its allies.
Draper Associates, founded in 1985, is a seed-stage venture capital firm that helps entrepreneurs to drive their businesses to greatness.
At One Ventures finds, funds, and grows teams to catalyze a world where humanity is a net positive to nature.
JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
The first venture firm with access to 100M+ engaged consumers across the world Driving growth by leveraging proprietary marketing channels and increasing consumer awareness.
GSV supports and partners with exceptional founders and entrepreneurs who push the boundaries of possibility and harness the power of science and technology to build better futures at scale.
Climate Capital invests alongside Tier 1 Seed investors into companies directly or indirectly chipping away at greenhouse gas emissions, or helping with adaptation.
Winklevoss Capital supports determined entrepreneurs by providing guidance, relationships and capital, helping to reinforce their pursuit of a frictionless world and a better human experience.
BOLD is a venture capital firm that seeks entrepreneurs and companies who share a fierce vision for a brighter tomorrow.
Boost VC is an early stage VC firm in San Mateo, CA founded by Adam Draper & Brayton Williams. They invest in pre-seed startups accelerating the Sci-Fi Future (aerospace, energy, climate, robotics, crypto, biotech, virtual reality & more).
Headquartered in the Chicago Board of Trade Building with offices worldwide, PEAK6 is powered by the same trading that got us our start. It fuels us to think outside the box and remain nimble.
The North Dakota Development Fund (NDDF) provides flexible financing for the purpose of economic development and expansion in the state of North Dakota.
We are honored to have legendary biotech investor, Robert Nelsen, behind Colossal’s mission.
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150 companies, including 39 which have reached valuations exceeding $1 billion. Mr. Nelsen is focused on generating new ideas for disruptive technologies or business models and partnering with founding management teams and entrepreneurs to execute on these visions by advancing novel platform technologies with the overarching goal of improving health care and outcomes.
[ Colossal INVESTOR ]
We couldn’t be more excited about collaborating with top universities in the U.S. and all over the world. Because as we step further into perfecting the science of de-extinction, it will always be of vital importance that we unite the greatest minds and research partners available. Leading the way to a better world simply wouldn’t be possible without these partnerships and the amazing work being done in our education institutions.
Preserving the planet through the de-extinction and protection of keystone species is an undertaking we can't achieve alone.
Each one of our conservation partners is thus vital to the cause, and as our studies lead to breakthroughs in genetics, we'll partner to help save existing species that are either threatened or in need of help. Together, the results will be Colossal.
Conserve & Protect :
The team at Colossal is committed, colorful, passionate, intelligent, collaborative, creative, experienced, scientific and world-class. That sounds like a lot to fit into one building. That’s why we are spread out in three locations that include laboratories, test facilities, academic institutions, libraries and offices.
Through it all, however, we maintain a culture of positivity, hope, happiness and belief that we’re doing something big. Something Colossal.
Awards & Acknowledgments :
With every breakthrough made at Colossal Biosciences, we take a step toward a better, brighter tomorrow. Thus, Colossal has been recognized for world-saving, life-changing, never-before-seen conservation and de-extinction efforts. Because our work is not done in vain—it’s done for the greater good and the health of our planet’s future.
Fast Company Most Innovative CompaniesBiotech